EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult CF Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02443688
Recruitment Status : Completed
First Posted : May 14, 2015
Last Update Posted : May 17, 2018
Information provided by (Responsible Party):
Celtaxsys, Inc.

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : April 20, 2018
  Actual Study Completion Date : May 16, 2018